Analysts See $-0.11 EPS for Biocept, Inc. (BIOC)

July 13, 2018 - By Mary Markley

Analysts expect Biocept, Inc. (NASDAQ:BIOC) to report $-0.11 EPS on August, 9.They anticipate $0.10 EPS change or 47.62 % from last quarter’s $-0.21 EPS. After having $-0.11 EPS previously, Biocept, Inc.’s analysts see 0.00 % EPS growth. The stock increased 9.77% or $0.64 during the last trading session, reaching $7.19. About 13.59M shares traded or 9973.87% up from the average. Biocept, Inc. (NASDAQ:BIOC) has declined 87.32% since July 14, 2017 and is downtrending. It has underperformed by 99.89% the S&P500.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $490.45 million. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.

More notable recent Biocept, Inc. (NASDAQ:BIOC) news were published by: Nasdaq.com which released: “Why RH, Biocept, and Lowe’s Jumped Today” on July 13, 2018, also Benzinga.com with their article: “44 Biggest Movers From Yesterday” published on July 13, 2018, Seekingalpha.com published: “Biocept tries to break downtrend, up 27%” on July 11, 2018. More interesting news about Biocept, Inc. (NASDAQ:BIOC) were released by: Benzinga.com and their article: “24 Stocks Moving In Friday’s Mid-Day Session” published on July 13, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Dow Rises 100 Points; Auris Medical Shares Slide” with publication date: July 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.